Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Regional Distribution and Evolution of Gray Matter Damage in Different Populations of Multiple Sclerosis Patients.
Results of a phase II placebo-controlled randomized trial of minocycline in acute spinal cord injury.
Review of the novelties presented at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (III).
Anatomical Brain Networks on the Prediction of Abnormal Brain States.
Personality traits of patients with multiple sclerosis and their relationship with clinical characteristics.
Neuromodulation of lower limb motor control in restorative neurology.
Lipocalin 2 is a novel immune mediator of experimental autoimmune encephalomyelitis pathogenesis and is modulated in multiple sclerosis.
[Neuromyelitis optica in the elderly: An unusual demyelinating disease.]
Exploration of the relationships between regional grey matter atrophy and cognition in multiple sclerosis.
Anti-inflammatory effects of levetiracetam in experimental autoimmune encephalomyelitis.
Cannabidiol protects oligodendrocyte progenitor cells from inflammation-induced apoptosis by attenuating endoplasmic reticulum stress.
Association of a deficit of arousal with fatigue in multiple sclerosis: Effect of modafinil.
Expression of Ccl11 Associates with Immune Response Modulation and Protection against Neuroinflammation in Rats.
Cross-Immunoreactivity between Bacterial Aquaporin-Z and Human Aquaporin-4: Potential Relevance to Neuromyelitis Optica.
Managing MS: Trends, Issues, and Perspectives.
The relationship between upper leg muscle strength and walking capacity in persons with multiple sclerosis.
[Biomarkers in neuromyelitis optica].
Teaching NeuroImages: MRI time lag with acute disseminated encephalomyelitis.
Limb ataxia originating from peri-central sulcus demyelinating lesion in multiple sclerosis.
[Treatment of nausea and vomiting with 5HT3 receptor antagonists, steroids, antihistamines, anticholinergics, somatostatinantagonists, benzodiazepines and cannabinoids in palliative care patients : A systematic review.]
Prostaglandin E2 inhibits IL-23 and IL-12 production by human monocytes through down-regulation of their common p40 subunit.
Increase of complement fragment C5a in cerebrospinal fluid during exacerbation of neuromyelitis optica.
Improved operator agreement and efficiency using the minimum area contour change method for delineation of hyperintense multiple sclerosis lesions on FLAIR MRI.
Paroxysmal atrial fibrillation after initiation of fingolimod for multiple sclerosis treatment.
The treatment of spasticity with Delta9-tetrahydrocannabinol in persons with spinal cord injury.
Pages
« first
‹ previous
…
230
231
232
233
234
235
236
237
238
…
next ›
last »